CorVel (NASDAQ:CRVL) Director Sells $110,449.02 in Stock

CorVel Corp. (NASDAQ:CRVL) Director R Judd Jessup sold 1,562 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $70.71, for a total transaction of $110,449.02. Following the completion of the sale, the director directly owned 117,083 shares of the company’s stock, valued at approximately $8,278,938.93. This trade represents a 1.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

R Judd Jessup also recently made the following trade(s):

• On Thursday, August 27th, R Judd Jessup sold 1,262 shares of CorVel stock. The shares were sold at an average price of $70.64, for a total transaction of $89,147.68.

CorVel Trading Up 0.3%

Shares of CRVL traded up $0.23 during trading hours on Friday, reaching $69.66. 42,589 shares of the stock traded hands, compared to its average volume of 218,616. The company has a market cap of $3.55 billion, a P/E ratio of 30.96 and a beta of 0.98. The company’s 50-day moving average price is $63.19 and its two-hundred day moving average price is $58.14. CorVel Corp. has a 52-week low of $44.83 and a 52-week high of $93.45.

CorVel (NASDAQ:CRVL) last issued its quarterly earnings results on Tuesday, August 4th. The business services provider reported $0.63 earnings per share (EPS) for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.72%.The business had revenue of $259.93 million during the quarter.

Institutional Trading of CorVel

A number of large investors have recently added to or reduced their stakes in CRVL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of CorVel by 0.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,961 shares of the business services provider’s stock valued at $1,640,000 after acquiring an additional 115 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in CorVel by 0.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,918 shares of the business services provider’s stock valued at $1,636,000 after purchasing an additional 139 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in CorVel by 18.9% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,228 shares of the business services provider’s stock valued at $77,000 after purchasing an additional 195 shares during the last quarter. Benjamin Edwards Inc. lifted its position in CorVel by 6.0% during the fourth quarter. Benjamin Edwards Inc. now owns 3,843 shares of the business services provider’s stock valued at $260,000 after purchasing an additional 218 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its stake in shares of CorVel by 66.9% in the 4th quarter. Rockefeller Capital Management L.P. now owns 574 shares of the business services provider’s stock worth $39,000 after buying an additional 230 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings upgraded CorVel from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 16th. Wall Street Zen upgraded shares of CorVel from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of “Hold”.

About CorVel

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).